Shares of Thyrocare Technologies Ltd Skyrocketed 18% on Thursday, 24 April, after the company reported strong financial results for the January-March quarter (Q4FY25).

The company’s net profit for the quarter ending March 2025 climbed by 21.9% year on year (YoY) to Rs 21.7 crore from Rs 17.8 crore in the same period last year. Profit growth was driven mostly by improved operational performance and a consistent increase in the number of diagnostic tests performed.

The revenue for the quarter increased by 21.3% YoY, from Rs 154.3 crore in Q4FY24 to Rs 187.2 crore. EBITDA, or earnings before interest, taxes, depreciation, and amortisation, increased by 70.5% to Rs 57.8 crore.

As a result, the EBITDA margin jumped to 30.9% from 22% during the same time last year. This signifies enhanced operational efficiency and cost control.

The company’s board has recommended a final dividend of Rs 21 per equity share for FY25; shareholder approval is currently pending.

Thyrocare, headquartered in Navi Mumbai, operates a vast network of diagnostic and preventative healthcare laboratories throughout India. In recent quarters, the company has concentrated on increasing its test offerings and strengthening its digital presence, which has contributed to revenue growth driven by increased testing volumes.

At 12:24 pm, the shares of Thyrocare Tech were trading 13.44% higher at Rs 872.60 on NSE. 

Wondering About Thyrocare Technologies Ltd? The Analyst Has Answers.

The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!